Angiogenesis has an essential role in tumor growth and metastasis, and blocking this
pathway has been a successfully utilized strategy in the clinical treatment of cancer …

Lung cancer is the leading cause of death in men and women worldwide, affecting millions
of people. Between the two types of lung cancers, non-small cell lung cancer (NSCLC) is …

Background This study evaluated the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …

Background Indole alkaloids are very promising for potential therapeutic purposes and
appear to be particularly effective against respiratory diseases. Several experimental studies …

Background Liver cancer is predicted to be the sixth most diagnosed cancer globally and
fourth leading cause of cancer deaths. In this study, a series of indole-3-isoxazole-5 …

Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Anlotinib is a novel molecular targeted drug that has been approved for the treatment of lung
adenocarcinoma. Currently these agents are rarely used in the treatment of lung squamous …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background The aim of this study was to investigate the efficacy and safety of anlotinib for
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …

Liver metastasis is common in advanced small cell lung cancer (SCLC). There is no
evidence‐proven treatment beyond the second line in patients with SCLC and liver …